Status:
TERMINATED
Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Lead Sponsor:
Helse Stavanger HF
Conditions:
Branch Retinal Vein Occlusion
Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether pars plana vitrectomy in combination with triamcinolone acetate is effective in the treatment of macular edema due to branch retinal vein occlusion.
Eligibility Criteria
Inclusion
- Macular edema secondary to BRVO
- Best Corrected Visual Acuity of ≤ 20/40 on ETDRS chart
- Duration no shorter than 3 months
- Duration no longer than 12 months
Exclusion
- Proliferations in study eye
- Blod in vitreous cavity
- Previous fundus laser treatment
- BRVO with over 180˚ of ischemia on FA
- Age under 18
- Other eye condition which contribute to relevant loss of visual acuity
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00642226
Start Date
November 1 2006
End Date
November 1 2013
Last Update
January 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stavanger University Hospital, Department of Ophthalmology
Stavanger, Norway, 4018